Computational identification of potential multi-drug combinations for reduction of microglial inflammation in Alzheimer disease

Frontiers in Pharmacology

Volumn 6, Issue JUN, 2015, Pages

  Anastasio, Thomas J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Computational biology; Microglia; Neurodegeneration; Polypharmacology; Systems biology

Indexed keywords

AURANOFIN; BORTEZOMIB; DASATINIB; FRACTALKINE; GAMMA INTERFERON; GLIMEPIRIDE; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; NALOXONE; NICOTINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; RUXOLITINIB; STAT1 PROTEIN; THALIDOMIDE; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ALZHEIMER DISEASE; ARTICLE; COMBINATION CHEMOTHERAPY; COMPUTER LANGUAGE; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; CYTOKINE PRODUCTION; DECLARATIVE PROGRAMMING; DOWN REGULATION; DRUG DATABASE; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; GENE EXPRESSION REGULATION; IMPERATIVE PROGRAMMING; MATHEMATICAL COMPUTING; MICROGLIAL INFLAMMATION; MONOTHERAPY; NEGATIVE FEEDBACK; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; POSITIVE FEEDBACK; PREDICTIVE VALUE; PROTEIN EXPRESSION; RELIABILITY; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84936949217     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00116     Document Type: Article

References (60)

1. Anastasio, T. J. (2014). Temporal-logic analysis of microglial phenotypic conversion with exposure to amyloid-β. Mol. Biosyst. 11, 434-453. doi: 10.1039/C4MB00457D
2. Armstrong, R. A. (2014). A critical analysis of the 'amyloid cascade hypothesis'. Folia Neuropathol. 52, 211-225. doi: 10.5114/fn.2014.45562
3. Bibi, F., Yasir, M., Sohrab, S. S., Azhar, E. I., Al-Qahtani, M. H., Abuzenadah, A. M., et al. (2014). Link between chronic bacterial inflammation and Alzheimer disease. CNS Neurol. Disord. Drug Targets 13, 1140-1147. doi: 10.2174/1871527313666140917115741
4. Butovsky, O., Talpalar, A. E., Ben-Yaakov, K., and Schwartz, M. (2005). Activation of microglia by aggregated β-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol. Cell. Neurosci. 29, 381-393. doi: 10.1016/j.mcn.2005.03.005
5. Campbell, R. K. (1998). Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 32, 1044-1052. doi: 10.1345/aph.17360
6. Caraci, F., Spampinato, S., Sortino, M. A., Bosco, P., Battaglia, G., Bruno, V., et al. (2012). Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection. Cell Tissue Res. 347, 291-301. doi: 10.1007/s00441-011-1230-6
7. Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., et al. (2006). Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 9, 917-924. doi: 10.1038/nn1715
8. Castellani, R. J., Lee, H. G., Siedlak, S. L., Nunomura, A., Hayashi, T., Nakamura, M., et al. (2009). Reexamining Alzheimer's disease: evidence for a protective role for amyloid-β protein precursor and amyloid-β. J. Alzheimers Dis. 18, 447-452. doi: 10.3233/JAD-2009-1151
9. Clavel, M., Durán, R., Eker, S., Lincoln, P., Martí-Oliet, N., Meseguer, J., et al. (2007). All About Maude-A High-Preformance Logical Framework: How to Specify, Program, and Verify Systems in Rewriting Logic. Berlin: Springer.
10. Combs, C. K., Johnson, D. E., Cannady, S. B., Lehman, T. M., and Landreth, G. E. (1999). Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of β-amyloid and prion proteins. J. Neurosci. 19, 928-939.
11. De Simone, R., Ajmone-Cat, M. A., Carnevale, D., and Minghetti, L. (2005). Activation of alpha7 nicotinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and prostaglandin E2 in rat microglial cultures. J. Neuroinflammation 2:4. doi: 10.1186/1742-2094-2-4
12. Fang, J., Rhyasen, G., Bolanos, L., Rasch, C., Varney, M., Wunderlich, M., et al. (2012). Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood 120, 858-867. doi: 10.1182/blood-2012-02-407999
13. Fernandez, A. M., and Torres-Aleman, I. (2012). The many faces of insulin-like peptide signalling in the brain. Nat. Rev. Neurosci. 13, 225-239. doi: 10.1038/nrn3209
14. Fisher, J., and Henzinger, T. A. (2007). Executable cell biology. Nat. Biotechnol. 25, 1239-1249. doi: 10.1038/nbt1356
15. Griffin, W. S., and Mrak, R. E. (2002). Interleukin-1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer's disease. J. Leukoc. Biol. 72, 233-238.
16. Hanzel, C. E., Pichet-Binette, A., Pimentel, L. S., Iulita, M. F., Allard, S., Ducatenzeiler, A., et al. (2014). Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol. Aging 35, 2249-2262. doi: 10.1016/j.neurobiolaging.2014.03.026
17. Hardy, J., Bogdanovic, N., Winblad, B., Portelius, E., Andreasen, N., Cedazo-Minguez, A., et al. (2014). Pathways to Alzheimer's disease. J. Intern. Med. 275, 296-303. doi: 10.1111/joim.12192
18. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. doi: 10.1126/science.1072994
19. Hopkins, A. L. (2008). Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4, 682-690. doi: 10.1038/nchembio.118
20. Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., et al. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur. J. Neurosci. 28, 20-29. doi: 10.1111/j.1460-9568.2008.06321.x
21. Huth, M., and Ryan, M. (2004). Logic in Computer Science: Modelling and Reasoning about Systems. Cambridge: Cambridge University Press.
22. Ingham, V., Williams, A., and Bate, C. (2014). Glimepiride reduces CD14 expression and cytokine secretion from macrophages. J. Neuroinflammation 11:115. doi: 10.1186/1742-2094-11-115
23. Jeon, K. I., Byun, M. S., and Jue, D. M. (2003). Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKβ subunit. Exp. Mol. Med. 35, 61-66. doi: 10.1038/emm.2003.9
24. Jeon, K. I., Jeong, J. Y., and Jue, D. M. (2000). Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J. Immunol. 164, 5981-5989. doi: 10.4049/jimmunol.164.11.5981
25. Johnston, H., Boutin, H., and Allan, S. M. (2011). Assessing the contribution of inflammation in models of Alzheimer's disease. Biochem. Soc. Trans. 39, 886-890. doi: 10.1042/BST0390886
26. Keith, C. T., Borisy, A. A., and Stockwell, B. R. (2005). Multicomponent therapeutics for networked systems. Nat. Rev. Drug Discov. 4, 71-78. doi: 10.1038/nrd1609
27. Kettenmann, H., Hanisch, U. K., Noda, M., and Verkhratsky, A. (2011). Physiology of microglia. Physiol. Rev. 91, 461-553. doi: 10.1152/physrev.00011.2010
28. Koenigsknecht-Talboo, J., and Landreth, G. E. (2005). Microglial phagocytosis induced by fibrillar β-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J. Neurosci. 25, 8240-8249. doi: 10.1523/JNEUROSCI.1808-05.2005
29. Lawasut, P., Chauhan, D., Laubach, J., Hayes, C., Fabre, C., Maglio, M., et al. (2012). New proteasome inhibitors in myeloma. Curr. Hematol. Malig. Rep. 7, 258-266. doi: 10.1007/s11899-012-0141-2
30. Lee, H. G., Casadesus, G., Zhu, X., Takeda, A., Perry, G., and Smith, M. A. (2004). Challenging the amyloid cascade hypothesis: senile plaques and amyloid-β as protective adaptations to Alzheimer disease. Ann. N.Y. Acad. Sci. 1019, 1-4. doi: 10.1196/annals.1297.001
31. Lee, S., Varvel, N. H., Konerth, M. E., Xu, G., Cardona, A. E., Ransohoff, R. M., et al. (2010). CX3CR1 deficiency alters microglial activation and reduces β-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 177, 2549-2562. doi: 10.2353/ajpath.2010.100265
32. Lehar, J., Krueger, A. S., Avery, W., Heilbut, A. M., Johansen, L. M., Price, E. R., et al. (2009). Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat. Biotechnol. 27, 659-666. doi: 10.1038/nbt.1549
33. Lewis, S. S., Loram, L. C., Hutchinson, M. R., Li, C. M., Zhang, Y., Maier, S. F., et al. (2012). (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. J. Pain 13, 498-506. doi: 10.1016/j.jpain.2012.02.005
34. Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., et al. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20, 5709-5714.
35. Loane, D. J., Deighan, B. F., Clarke, R. M., Griffin, R. J., Lynch, A. M., and Lynch, M. A. (2009). Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain. Neurobiol. Aging 30, 920-931. doi: 10.1016/j.neurobiolaging.2007.09.001
36. Mandrekar-Colucci, S., and Landreth, G. E. (2010). Microglia and inflammation in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 9, 156-167. doi: 10.2174/187152710791012071
37. Matthews, S. J., and McCoy, C. (2003). Thalidomide: a review of approved and investigational uses. Clin. Ther. 25, 342-395. doi: 10.1016/S0149-2918(03)80085-1
38. McDonald, D. R., Brunden, K. R., and Landreth, G. E. (1997). Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J. Neurosci. 17, 2284-2294.
39. Miklossy, J. (2008). Chronic inflammation and amyloidogenesis in Alzheimer's disease-role of Spirochetes. J. Alzheimers Dis. 13, 381-391.
40. Moon, J. H., Kim, S. Y., Lee, H. G., Kim, S. U., and Lee, Y. B. (2008). Activation of nicotinic acetylcholine receptor prevents the production of reactive oxygen species in fibrillar β amyloid peptide (1-42)-stimulated microglia. Exp. Mol. Med. 40, 11-18. doi: 10.3858/emm.2008.40.1.11
41. Nam, S., Williams, A., Vultur, A., List, A., Bhalla, K., Smith, D., et al. (2007). Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 6, 1400-1405. doi: 10.1158/1535-7163.MCT-06-0446
42. Necela, B. M., Su, W., and Thompson, E. A. (2008). Toll-like receptor 4 mediates cross-talk between peroxisome proliferator-activated receptor gamma and nuclear factor-kappaB in macrophages. Immunology 125, 344-358. doi: 10.1111/j.1365-2567.2008.02849.x
43. Noman, A. S., Koide, N., Hassan, F., E-Khuda, I. I., Dagvadorj, J., Tumurkhuu, G., et al. (2009). Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production via down-regulation of MyD88 expression. Innate Immun. 15, 33-41. doi: 10.1177/1753425908099317
44. Park, B. S., Song, D. H., Kim, H. M., Choi, B. S., Lee, H., and Lee, J. O. (2009). The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458, 1191-1195. doi: 10.1038/nature07830
45. Piazza, A., and Lynch, M. A. (2009). Neuroinflammatory changes increase the impact of stressors on neuronal function. Biochem. Soc. Trans. 37, 303-307. doi: 10.1042/BST0370303
46. Ransohoff, R. M., and Perry, V. H. (2009). Microglial physiology: unique stimuli, specialized responses. Annu. Rev. Immunol. 27, 119-145. doi: 10.1146/annurev.immunol.021908.132528
47. Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., and Landreth, G. E. (2009). CD14 and toll-like receptors 2 and 4 are required for fibrillar A{β}-stimulated microglial activation. J. Neurosci. 29, 11982-11992. doi: 10.1523/JNEUROSCI.3158-09.2009
48. Reitz, C. (2012). Alzheimer's disease and the amyloid cascade hypothesis: a critical review. Int. J. Alzheimers Dis. 2012, 369808. doi: 10.1155/2012/369808
49. Shytle, R. D., Mori, T., Townsend, K., Vendrame, M., Sun, N., Zeng, J., et al. (2004). Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J. Neurochem. 89, 337-343. doi: 10.1046/j.1471-4159.2004.02347.x
50. Skaper, S. D. (2012). Alzheimer's disease and amyloid: culprit or coincidence? Int. Rev. Neurobiol. 102, 277-316. doi: 10.1016/b978-0-12-386986-9.00011-9
51. Smith, K., Hopp, M., Mundin, G., Bond, S., Bailey, P., Woodward, J., et al. (2012). Low absolute bioavailability of oral naloxone in healthy subjects. Int. J. Clin. Pharmacol. Ther. 50, 360-367. doi: 10.5414/CP201646
52. Sung, S., Yang, H., Uryu, K., Lee, E. B., Zhao, L., Shineman, D., et al. (2004). Modulation of nuclear factor-kappa B activity by indomethacin influences A β levels but not A β precursor protein metabolism in a model of Alzheimer's disease. Am. J. Pathol. 165, 2197-2206. doi: 10.1016/S0002-9440(10)63269-5
53. Verstovsek, S. (2013). Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad. Med. 125, 128-135. doi: 10.3810/pgm.2013.01.2628
54. Von Bernhardi, R. (2007). Glial cell dysregulation: a new perspective on Alzheimer disease. Neurotox. Res. 12, 215-232. doi: 10.1007/BF03033906
55. Wang, L., Xu, Y. L., and Zhang, X. Q. (2014). Bortezomib in combination with thalidomide or lenalidomide or doxorubicin regimens for the treatment of multiple myeloma: a meta-analysis of 14 randomized controlled trials. Leuk. Lymphoma 55, 1479-1488. doi: 10.3109/10428194.2013.838232
56. Wilkinson, B., Koenigsknecht-Talboo, J., Grommes, C., Lee, C. Y., and Landreth, G. (2006). Fibrillar β-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J. Biol. Chem. 281, 20842-20850. doi: 10.1074/jbc.M600627200
57. Wong, W. T. (2013). Microglial aging in the healthy CNS: phenotypes, drivers, and rejuvenation. Front. Cell. Neurosci. 7:22. doi: 10.3389/fncel.2013.00022
58. Xie, L., Xie, L., Kinnings, S. L., and Bourne, P. E. (2012). Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu. Rev. Pharmacol. Toxicol. 52, 361-379. doi: 10.1146/annurev-pharmtox-010611-134630
59. Yan, Q., Zhang, J., Liu, H., Babu-Khan, S., Vassar, R., Biere, A. L., et al. (2003). Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504-7509.
60. Yarilina, A., Xu, K., Chan, C., and Ivashkiv, L. B. (2012). Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors. Arthritis Rheum. 64, 3856-3866. doi: 10.1002/art.37691